Using a CX43 inhibitor, reduced α-synuclein deposits and attenuated neuroinflammation in a PD rat model were observed (164), highlighting the therapeutic potential of CX43 in several neurodegenerative diseases. Here, SNCA is linked to Parkinson disease.